VA
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors | Cancer research communications |  | 2024 | 85 | 84 | ||
| LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy | ESMO Congress 2023 | | 2023 | 65 | 25 | ||
| Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors | ESMO Congress 2022 | | 2022 | 69 | 82 | ||
| Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites | Clinical Pharmacokinetics | | 2018 | 681 | 691 | ||
| Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers | Basic & clinical pharmacology & toxicology | | 2013 | 630 | 399 | ||
| The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro | British journal of pharmacology |  | 2012 | 554 | 0 | ||
| Inhibiteurs des récepteurs plaquettaires P2Y12 à l'ADP: importance du métabolisme et influence des interactions médicamenteuses sur leurs paramètres pharmacocinétiques | | 2012 | 1,076 | 2,153 | |||
| Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients | Metabolism, clinical and experimental | 2011 | 664 | 0 | |||
| Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability | Current drug metabolism | 2010 | 648 | 0 |
